drugset / Trial / NCT05010200
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
Non-randomizedSequentialOpen-labelPrevention
Summary
This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor free adjuvant setting.
Timeline
- Start
- 2022-01-05
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-301 | Protein / enzyme biologic | — | — |
| Subject | PGV001 | Vaccine | — | — |
| Background | Hiltonol | Other / unclassified | — | — |